425: Hepion Pharmaceuticals to Merge with Pharma Two B, Aiming for Nasdaq Listing and Parkinson's Treatment Advancement

Hepion Pharmaceuticals plans to merge with Pharma Two B, a late-clinical stage Israeli company, to advance the development of P2B001 for Parkinson's Disease and list on Nasdaq, accompanied by a $11.5 million private placement.

Summary

• Hepion Pharmaceuticals and Pharma Two B have entered into a definitive merger agreement.
• Following the merger, Hepion will become an indirect wholly-owned subsidiary of Pharma Two B.
• Pharma Two B will apply to list its ordinary shares on Nasdaq under the ticker symbol PHTB.
• A registration statement on Form F-4 will be filed with the SEC to register the ordinary shares to be issued to Hepion's equity holders.
• Immediately upon completion of the merger, current Pharma Two B equity-holders will own approximately 85% of the combined company and current Hepion equity-holders will own approximately 15% of the combined company, in each case on a pro forma basis, subject to certain adjustments set forth in the merger agreement and prior to closing of the concurrent private financing.
• Immediately upon closing of the $11.5 million concurrent private financing, current Pharma Two B equity-holders will own approximately 44.5% of the combined company, current Hepion equity-holders will own approximately 7.8% of the combined company, and investors in the concurrent private financing will own approximately 47.7% of the combined company, in each case on a pro forma basis, subject to certain adjustments set forth in the merger agreement.
• Pharma Two B is developing P2B001, a combination product candidate for the treatment of Parkinson's Disease.
• An NDA submission for P2B001 is planned for the first half of 2026.
• Hepion has entered into a purchase agreement for the sale of $2.9 million in senior unsecured notes.
• Hepion will loan $600,000 of the proceeds to Pharma Two B, which will be forgiven upon consummation of the merger.
• The merger is expected to close in the fourth quarter of 2024, pending stockholder and regulatory approvals.
• The Series A warrants will have a 5-year term, and an exercise price of $6.00 per ordinary share.
• The Series B warrants will have a 2.5-year term, and an exercise price of $6.00 per ordinary share.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The merger provides a path forward for both companies, but there are risks associated with regulatory approvals and market conditions. The focus on a late-stage asset is encouraging.

Positives

• Merger provides Hepion stockholders with an opportunity to participate in a company with a promising late-stage asset.
• P2B001 addresses an unmet need in Parkinson's Disease treatment with a novel, easy-to-use therapeutic approach.
• The $11.5 million private placement will provide the combined company with additional capital to advance P2B001.
• Listing on Nasdaq will increase the company's visibility and access to capital markets.
• Hepion's existing stockholders will retain a portion of the combined company's equity.

Negatives

• Hepion's stockholders will experience significant dilution as a result of the merger and private placement.
• Hepion is winding down its ASCEND-NASH clinical trial, indicating a shift away from its primary asset, Rencofilstat.
• The merger is subject to stockholder and regulatory approvals, and may not be completed.
• The combined company will be heavily reliant on the success of P2B001, which is still subject to regulatory approval.

Risks

• The merger may not be completed in a timely manner or at all.
• Pharma Two B may not be able to meet Nasdaq initial listing standards.
• The combined company may not be able to realize the anticipated benefits of the merger.
• P2B001 may not receive regulatory approval or be commercially successful.
• The combined company may require additional capital in the future.
• The Series A warrants and Series B warrants have anti-dilution price protection and share adjustment features, subject to a floor price of 20% of the initial exercise price per share, as well as a cash true up feature, in each case subject to certain limitations.

Future Outlook

The combined company will focus on advancing P2B001 for Parkinson's Disease, with an NDA submission targeted for the first half of 2026. The company intends to use net proceeds to fund continuing growth and expansion of its lead product candidate P2B001.

Management Comments

• Dan Teleman, Chief Executive Officer of Pharma Two B, stated that P2B001 offers a novel, easy-to-use therapeutic approach for Parkinson's disease patients.
• John Brancaccio, Executive Chairman, stated that the transaction with Pharma Two B presents an excellent opportunity for Hepion shareholders to become a part of a company poised to file an NDA in a therapeutic area with a major unmet medical need.

Industry Context

The announcement reflects a trend of pharmaceutical companies merging to consolidate resources and advance drug development pipelines, particularly in areas with high unmet medical needs like Parkinson's Disease.

Comparison to Industry Standards

• The merger is similar to other reverse merger transactions in the biopharmaceutical industry, where a private company merges with a publicly listed shell company to gain access to public markets.
• The $11.5 million private placement is a common financing strategy for companies in this sector to fund clinical trials and other development activities.
• The planned NDA submission for P2B001 in 2026 aligns with typical timelines for drug development in the pharmaceutical industry.
• The ownership split between Pharma Two B and Hepion equity holders is within the range observed in similar merger transactions.

Stakeholder Impact

• Hepion stockholders will receive ordinary shares of Pharma Two B, providing them with potential upside in a new company.
• Pharma Two B will gain access to public markets and additional capital to support its development programs.
• Patients with Parkinson's Disease may benefit from the development of P2B001, a novel treatment option.

Next Steps

• Hepion will seek stockholder approval for the merger.
• Pharma Two B will file a registration statement on Form F-4 with the SEC.
• The companies will work to satisfy regulatory requirements and other closing conditions.
• Pharma Two B will apply to list its ordinary shares on Nasdaq.
• Pharma Two B will close the $11.5 million private placement.
• Pharma Two B will advance the development of P2B001 and prepare for an NDA submission.

Key Dates

Keywords

merger, Pharma Two B, Hepion Pharmaceuticals, P2B001, Parkinson's Disease, NDA submission, private placement, Nasdaq listing, Rencofilstat, biopharmaceutical